Ascend Wellness Reports Q1 2026: Revenue & EBITDA Decline, Net Loss Improves, Q2 Outlook Positive
AAWH has more than doubled off its 52-week low of $0.26.
Summary
Ascend Wellness Holdings reported a sequential decline in Q1 2026 revenue and Adjusted EBITDA, but an improved net loss and gross margin, alongside a positive Q2 outlook and strategic benefits from cannabis rescheduling.
Key Events · Earnings and Guidance · AAWH
-
Q1 2026 Financial Performance
Net revenue declined to $116.9 million (down 3.0% sequentially, 8.6% YoY), and Adjusted EBITDA fell to $26.3 million (down 12.9% sequentially, 2.5% YoY). Net loss improved sequentially to $29.5 million from $48.7 million in Q4 2025, and Adjusted Gross Profit Margin increased to 46.1%.
-
Cash Position and Outflow
The company reported $60.9 million in cash and cash equivalents. Net cash outflow from operating activities was $19.4 million, including a $19.1 million bi-annual interest payment and a $17.0 million arbitration settlement payment.
-
Operational Expansion and Brand Strength
Ascend added five new dispensaries year-to-date and plans for 10 more, aiming for 60 stores by year-end. Its Ozone and High Wired brands showed strong performance, with High Wired ranking #1 in the infused flower category in key markets.
-
Q2 2026 Outlook
The company anticipates a 2-3% increase in revenue and expects Adjusted EBITDA Margin to remain in the low-20% range, driven by new store openings and favorable seasonality.
Analysis · AAWH · Life Sciences
Ascend Wellness Holdings reported mixed Q1 2026 financial results, with both net revenue and Adjusted EBITDA declining sequentially and year-over-year. However, the company saw an improvement in its net loss compared to the previous quarter and an increase in Adjusted Gross Profit Margin. A significant cash outflow from operations was noted, partly due to a large interest payment and an arbitration settlement. Operationally, the company is expanding its retail footprint and seeing strong brand performance. The positive outlook for Q2 2026 revenue growth and stable EBITDA margins, coupled with the potential benefits from the rescheduling of medical cannabis, provides some optimism amidst ongoing financial challenges.
At the time of this filing, AAWH was trading at $0.57 on OTC in the Life Sciences sector, with a market capitalization of approximately $115.2M. The 52-week trading range was $0.26 to $1.20. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.